Search Medical Condition
Please enter condition
Please choose location from dropdown

North Shields, United Kingdom Clinical Trials

A listing of North Shields, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (273) clinical trials

The British Heart Foundation SENIOR-RITA Trial

The population is getting older and heart artery disease is the biggest killer in the UK. Over recent years, there have been improvements in medications and technologies to treat it, but these have been primarily tested in younger patients. Previous research studies suggest that older patients (75 years and over) ...

Phase N/A

2.79 miles

Learn More »

ObeSity Related Colorectal Adenoma Risk

Bowel cancer, or colorectal cancer (CRC), is the second most common cancer affecting both men and women in England. The majority of CRCs develop from a pre-cancerous type of growth in the bowel called an adenoma. Detecting and removing these adenomas is important in reducing CRC risk. A study which ...

Phase N/A

2.79 miles

Learn More »

Efficacy Study for Geko Device in VLU Patients

Screen patient database to identify eligible patients Obtain informed consent and inform participant's GP Complete CRF throughout the study period (demographics, vital signs, medical history, study ulcer history, concomitant medication) Physical examination at the study start up visit and at consecutive weekly visits Take a digital image of the wound ...

Phase

3.02 miles

Learn More »

Validation of the Spasticity Related Quality of Life Questionnaire

The study qualifies as interventional not because of the use of an investigational product, but because the imposed specific data collection procedures include multiple questionnaire assessments and one on-site visit not necessarily part of routine clinical practice.

Phase N/A

4.7 miles

Learn More »

A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of cell cycle progression and the DNA Damage Response (DDR) replication stress response. In cancer cells, intrinsic replication stress (RS) is induced by factors such as oncogenes (e.g., CCNE1 or MYC), genetic mutations in ...

Phase

5.74 miles

Learn More »

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.

Phase

5.74 miles

Learn More »

A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Parts A and B will consist of 3 periods: Screening, Treatment and Follow-up. Screening Period The Screening Period starts 28 days ( 3 days) prior to first dose of CC-90011. The informed consent document (ICD) must be signed and dated by the subject and the administering staff prior to the ...

Phase

5.74 miles

Learn More »

Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery

The EMINENT study is a prospective, multi-center study confirming the superior effectiveness of the ELUVIA stent versus Self-Expanding Bare Nitinol Stents in the treatment of lesions 30-210 mm long located in the femoropopliteal arteries in subjects with symptoms classified as Rutherford categories 2-4. The study is a 2:1 randomized (ELUVIA ...

Phase N/A

5.74 miles

Learn More »

Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis

This clinical investigation is a medical device trial to examine the safety and efficacy of TheraSorb sFlt-1 adsorber treatment of pregnant patients with preeclampsia.

Phase N/A

5.74 miles

Learn More »

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint ...

Phase

5.74 miles

Learn More »